140 related articles for article (PubMed ID: 36552804)
21. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
[TBL] [Abstract][Full Text] [Related]
22. miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
Li J; Fu R; Yang L; Tu W
Int J Clin Exp Pathol; 2015; 8(11):15019-24. PubMed ID: 26823838
[TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase regulates B cell antigen receptor-mediated JNK1 response through Rac1 and phospholipase C-gamma2 activation.
Inabe K; Miyawaki T; Longnecker R; Matsukura H; Tsukada S; Kurosaki T
FEBS Lett; 2002 Mar; 514(2-3):260-2. PubMed ID: 11943162
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic value of secreted protein acidic and rich in cysteine in the diffuse large B-cell lymphoma.
Pan PJ; Liu JX
World J Clin Cases; 2021 Aug; 9(22):6287-6299. PubMed ID: 34434995
[TBL] [Abstract][Full Text] [Related]
25. Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression.
Zhao F; Li S; Liu J; Wang J; Yang B
Hum Cell; 2022 Jul; 35(4):1234-1247. PubMed ID: 35676608
[TBL] [Abstract][Full Text] [Related]
26. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
28. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
29. FilGAP, a Rac-specific Rho GTPase-activating protein, is a novel prognostic factor for follicular lymphoma.
Nishi T; Takahashi H; Hashimura M; Yoshida T; Ohta Y; Saegusa M
Cancer Med; 2015 Jun; 4(6):808-18. PubMed ID: 25641953
[TBL] [Abstract][Full Text] [Related]
30. Expression and clinical significance of ubiquitin‑specific‑processing protease 34 in diffuse large B‑cell lymphoma.
Li C; Huang L; Lu H; Wang W; Chen G; Gu Y; Zhou Q; Peng Z; Feng Z
Mol Med Rep; 2018 Nov; 18(5):4543-4554. PubMed ID: 30221700
[TBL] [Abstract][Full Text] [Related]
31. MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma.
Ye H; Lu L; Ge B; Gao S; Ma Y; Liang B; Yu K; Yang K
Int J Clin Exp Pathol; 2015; 8(10):13043-50. PubMed ID: 26722499
[TBL] [Abstract][Full Text] [Related]
32. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
Zheng W; Lin Q; Issah MA; Liao Z; Shen J
BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
[TBL] [Abstract][Full Text] [Related]
33. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
34. Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma.
Sun C; Cheng X; Wang C; Wang X; Xia B; Zhang Y
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30393234
[TBL] [Abstract][Full Text] [Related]
35. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
37. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
[TBL] [Abstract][Full Text] [Related]
38. Expression of SATB1 is a prognostic indicator for survival in diffuse large B-cell lymphoma patients.
Yi H; Wei Y; Chen JJ
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):382-390. PubMed ID: 35113413
[TBL] [Abstract][Full Text] [Related]
39. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
